- Cranbury, NJ-based Oncobiologics (NASDAQ:ONS-OLD) is set for its IPO of 5M shares of common stock at $11 - 13.
- The clinical-stage biopharmaceutical firm develops biosimilars in immunology and oncology based on its proprietary BioSymphony Platform. Its most advanced candidates are ONS-3010, a biosimilar of AbbVie's (NYSE:ABBV) Humira (adalimumab) and ONS-1045, a biosimilar of Roche's (OTCQX:RHHBY) Avastin (bevacizumab). According to the company, both are Phase 3-ready.
- Other pipeline candidates are ONS-4010 [biosimilar of Amgen's (NASDAQ:AMGN) Prolia/Xgeva (denosumab)], ONS-1055 [biosimilar of Eli Lilly's (NYSE:LLY) Erbitux (cetuximab)] and ONS-3030 [biosimilar of Roche's Actemra/Roactemra (tocilizumab)].
- 2015 Financials ($M): Collaboration Revenue: 5.2 (-42.9%); Operating Expenses: 51.8 (+142.1%); Net Loss: (53.0) (-156.0%); Cash Burn: (27.5) (-292.9%).